Deliverable: Transcript and abstract

Objectives:

·         Determine current treatment patterns, recent market dynamics, and future trends with the mix of leading Type 2 therapies, including Byetta (exenatide), Januvia (sitagliptin) and Other standards of care (metformin, TZD’s, sulfonylureas, insulin)

·         Understand Byetta utilization

·         Clarify physician prescribing experience with Byetta

·         Determine potential use and impact of Byetta LAR

Products Highlighted:

·         Byetta® (exenatide), Amylin/Lilly

·         Januvia™ (sitagliptin), Merck

·         Byetta® LAR (long-acting exenatide)

·         Metformin

·         Thiazolidinediones (TZDs)

·         Sulfonylureas

·         Insulin

Topics:

·         Patient types and rationale for prescribing

·         Treatment regimen

·         Changes in treatment algorithms and standard of care

·         Market dynamics since launch, including impact of Januvia

·         Other competition & perceptions

·         Strengths, weaknesses, treatment outcomes

·         Drivers of usage

·         Patient experience

·         Sampling

·         Reimbursement experience

·         Regional differences & drivers

Screening Criteria:

Eight physicians – endocrinologists and primary care physicians

• US-based professionals with a geographic distribution
• High-volume community-based practitioners with large Type 2 diabetes practices
• Significant experience prescribing Byetta® (exenatide)

Representative Institutions: